Matthew J Worley1,2, Keith G Heinzerling3, Steven Shoptaw3, Walter Ling4. 1. Department of Psychiatry, University of California, San Diego, CA, USA. 2. Veterans Affairs San Diego Healthcare System, San Diego, CA, USA. 3. Department of Family Medicine, University of California, Los Angeles, CA, USA. 4. Department of Psychiatry, University of California, Los Angeles, CA, USA.
Abstract
BACKGROUND AND AIMS: Buprenorphine-naloxone (BUP-NLX) can be used to manage prescription opioid addiction among persons with chronic pain, but post-treatment relapse is common and difficult to predict. This study estimated whether changes in pain over time and pain volatility during BUP-NLX maintenance would predict opioid use during the taper BUP-NLX taper. DESIGN: Secondary analysis of a multi-site clinical trial for prescription opioid addiction, using data obtained during a 12-week BUP-NLX stabilization and 4-week BUP-NLX taper. SETTING: Community clinics affiliated with a national clinical trials network in 10 US cities. PARTICIPANTS: Subjects with chronic pain who entered the BUP-NLX taper phase (n = 125) with enrollment occurring from June 2006 to July 2009 (52% male, 88% Caucasian, 31% married). MEASUREMENTS: Outcomes were weekly biologically verified and self-reported opioid use from the 4-week taper phase. Predictors were estimates of baseline severity, rate of change and volatility in pain from weekly self-reports during the 12-week maintenance phase. FINDINGS: Controlling for baseline pain and treatment condition, increased pain [odds ratio (OR) = 2.38, P = 0.02] and greater pain volatility (OR = 2.43, P = 0.04) predicted greater odds of positive opioid urine screen during BUP-NLX taper. Increased pain (IRR = 1.40, P = 0.04) and greater pain volatility [incidence-rate ratio (IRR) = 1.66, P = 0.009] also predicted greater frequency of self-reported opioid use. CONCLUSIONS: Adults with chronic pain receiving out-patient treatment with buprenorphine-naloxone (BUP-NLX) for prescription opioid addiction have an elevated risk for opioid use when tapering off maintenance treatment. Those with relative persistence in pain over time and greater volatility in pain during treatment are less likely to sustain abstinence during BUP-NLX taper.
BACKGROUND AND AIMS: Buprenorphine-naloxone (BUP-NLX) can be used to manage prescription opioid addiction among persons with chronic pain, but post-treatment relapse is common and difficult to predict. This study estimated whether changes in pain over time and pain volatility during BUP-NLX maintenance would predict opioid use during the taper BUP-NLX taper. DESIGN: Secondary analysis of a multi-site clinical trial for prescription opioid addiction, using data obtained during a 12-week BUP-NLX stabilization and 4-week BUP-NLX taper. SETTING: Community clinics affiliated with a national clinical trials network in 10 US cities. PARTICIPANTS: Subjects with chronic pain who entered the BUP-NLX taper phase (n = 125) with enrollment occurring from June 2006 to July 2009 (52% male, 88% Caucasian, 31% married). MEASUREMENTS: Outcomes were weekly biologically verified and self-reported opioid use from the 4-week taper phase. Predictors were estimates of baseline severity, rate of change and volatility in pain from weekly self-reports during the 12-week maintenance phase. FINDINGS: Controlling for baseline pain and treatment condition, increased pain [odds ratio (OR) = 2.38, P = 0.02] and greater pain volatility (OR = 2.43, P = 0.04) predicted greater odds of positive opioid urine screen during BUP-NLX taper. Increased pain (IRR = 1.40, P = 0.04) and greater pain volatility [incidence-rate ratio (IRR) = 1.66, P = 0.009] also predicted greater frequency of self-reported opioid use. CONCLUSIONS: Adults with chronic pain receiving out-patient treatment with buprenorphine-naloxone (BUP-NLX) for prescription opioid addiction have an elevated risk for opioid use when tapering off maintenance treatment. Those with relative persistence in pain over time and greater volatility in pain during treatment are less likely to sustain abstinence during BUP-NLX taper.
Authors: Ludmila Cofta-Woerpel; Jennifer B McClure; Yisheng Li; Diana Urbauer; Paul M Cinciripini; David W Wetter Journal: J Abnorm Psychol Date: 2011-08
Authors: John S Cacciola; Arthur I Alterman; A Thomas McLellan; Yi-Ting Lin; Kevin G Lynch Journal: Drug Alcohol Depend Date: 2006-10-11 Impact factor: 4.492
Authors: San Keller; Carla M Bann; Sheri L Dodd; Jeff Schein; Tito R Mendoza; Charles S Cleeland Journal: Clin J Pain Date: 2004 Sep-Oct Impact factor: 3.442
Authors: Declan T Barry; Jonathan D Savant; Mark Beitel; Christopher J Cutter; Brent A Moore; Richard S Schottenfeld; David A Fiellin Journal: Am J Addict Date: 2013 May-Jun
Authors: Mary Jo Larson; Michael Paasche-Orlow; Debbie M Cheng; Christine Lloyd-Travaglini; Richard Saitz; Jeffrey H Samet Journal: Addiction Date: 2007-05 Impact factor: 6.526
Authors: Victoria D Powell; Jack M Rosenberg; Avani Yaganti; Claire Garpestad; Pooja Lagisetty; Carol Shannon; Maria J Silveira Journal: JAMA Netw Open Date: 2021-09-01
Authors: Nicholas Avery; Amy G McNeilage; Fiona Stanaway; Claire E Ashton-James; Fiona M Blyth; Rebecca Martin; Ali Gholamrezaei; Paul Glare Journal: BMJ Date: 2022-04-04
Authors: Amie L Severino; Arash Shadfar; Joshua K Hakimian; Oliver Crane; Ganeev Singh; Keith Heinzerling; Wendy M Walwyn Journal: Front Psychiatry Date: 2018-04-23 Impact factor: 4.157
Authors: Quazi Abidur Rahman; Tahir Janmohamed; Meysam Pirbaglou; Hance Clarke; Paul Ritvo; Jane M Heffernan; Joel Katz Journal: J Med Internet Res Date: 2018-11-15 Impact factor: 5.428